The funds raised will be used to advance Invictus’ lead molecule for completion of phase I clinical studies and to file an IND
Ratan N Tata, Chairman Emeritus, Tata Sons, has invested in Invictus Oncology, an innovation-driven oncology company developing next generation cancer therapeutics, as part of the first close of Invictus’s Series A financing round, joining existing investors Navam Capital and Aarin Capital.
The funds raised will be used to advance Invictus’ lead molecule for completion of Phase I clinical studies, and to file a second Investigational New Drug (IND) application; milestones which translate into substantial value inflections for Invictus Oncology over the next 12-18 months.
EP News Bureau – Mumbai
- Advertisement -
Comments are closed.